(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of -75.03% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Stoke Therapeutics's revenue in 2025 is $199,894,000.On average, 6 Wall Street analysts forecast STOK's revenue for 2025 to be $9,965,348,843, with the lowest STOK revenue forecast at $9,436,115,380, and the highest STOK revenue forecast at $10,420,824,981. On average, 5 Wall Street analysts forecast STOK's revenue for 2026 to be $1,246,202,880, with the lowest STOK revenue forecast at $246,588,381, and the highest STOK revenue forecast at $1,917,909,630.
In 2027, STOK is forecast to generate $2,147,346,419 in revenue, with the lowest revenue forecast at $876,758,688 and the highest revenue forecast at $4,676,959,626.